Successful bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning

Blood. 2007 Jan 1;109(1):383-5. doi: 10.1182/blood-2006-05-025072. Epub 2006 Sep 21.

Abstract

Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome is a rare, fatal autoimmune disorder caused by mutations in the FOXP3 gene leading to the disruption of signaling pathways involved in regulatory T-lymphocyte function. Lifelong multiagent immunosuppression is necessary to control debilitating autoimmune manifestations such as colitis and food allergies. Allogeneic hematopoietic stem cell transplantation (HSCT) can restore T-cell regulatory function but has been previously associated with poor outcome. We describe successful HSCT in 4 patients with IPEX syndrome using a novel reduced-intensity conditioning regimen that resulted in stable donor engraftment, reconstitution of FOXP3+ T regulatory CD4+ cells, and amelioration of gastrointestinal symptoms.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alemtuzumab
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • Bone Marrow Transplantation*
  • Child
  • Child, Preschool
  • Colitis / genetics
  • Endocrine System Diseases / genetics
  • Endocrine System Diseases / surgery*
  • Food Hypersensitivity / genetics
  • Forkhead Transcription Factors / deficiency
  • Genes, X-Linked
  • Graft Survival
  • Humans
  • Ichthyosis, X-Linked / genetics
  • Ichthyosis, X-Linked / surgery*
  • Immunologic Deficiency Syndromes / genetics
  • Immunologic Deficiency Syndromes / surgery*
  • Infant
  • Leukocyte Count
  • Melphalan
  • Postoperative Complications
  • Reoperation
  • Syndrome
  • Transplantation Conditioning / methods*
  • Transplantation, Homologous
  • Vidarabine / analogs & derivatives

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • FOXP3 protein, human
  • Forkhead Transcription Factors
  • Alemtuzumab
  • Vidarabine
  • fludarabine
  • Melphalan